XML 114 R103.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Jun. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Segment Reporting [Abstract]                
Net loss attributable to common shareholders of Evolent Health, Inc. - Basic $ (13,040,000) $ (37,348,000)         $ (31,954,000) $ (319,621,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted (13,040,000) (37,348,000)         (31,954,000) (319,621,000)
Interest income 120,000 1,159,000         311,000 2,634,000
Interest expense (6,367,000) (7,416,000)         (18,978,000) (19,987,000)
(Provision) benefit for income taxes (234,000) (503,000)         (936,000) 3,131,000
Depreciation and amortization expenses (14,859,000) (14,534,000)         (44,962,000) (46,130,000)
Equity method investment impairment 0 0         0 (47,133,000)
Gain on transfer of membership 0 0         22,969,000 0
Loss on repayment of debt, net 0 0         (19,158,000) 0
Loss on extinguishment of debt 0 (4,789,000)         0 (4,789,000)
Impairment 0 0 $ (215,100,000) $ 0 $ (199,800,000) $ (215,100,000) 0 (215,100,000)
Gain from equity method investees 63,000 (13,717,000)         12,725,000 11,014,000
Loss on disposal of assets 0 0         0 (6,447,000)
Change in fair value of contingent consideration and indemnification asset 225,000 (2,570,000)         819,000 492,000
Net loss attributable to non-controlling interests 0 822,000         0 822,000
Other income (expense), net (41,000) (110,000)         (73,000) 174,000
Repositioning costs 0 0         (6,043,000) 0
Stock-based compensation expense (4,395,000) (3,164,000)         (11,754,000) (10,375,000)
Severance costs 0 (1,757,000)         (52,000) (7,890,000)
Amortization of contract cost assets (110,000) (2,610,000)         (433,000) (3,817,000)
Strategy and shareholder advisory expenses 0 0         (6,513,000) 0
Acquisition costs (1,207,000) (807,000)         (3,277,000) (1,490,000)
Gain (loss) from discontinued operations [1] 0 (1,135,000)         1,383,000 (2,908,000)
Adjusted EBITDA $ 13,765,000 $ 13,783,000         $ 42,018,000 $ 28,178,000
[1] Includes $1.9 million gain on disposal of discontinued operations for the nine months ended September 30, 2021